Introduction: Viral hepatitis B (VHB) is a serious and global public health issue, particularly in sub-Saharan Africa where it is endemic. The objective of this work was to evaluate the effectiveness and safety of tenofovir disoproxil fumarate (TDF) in the treatment of chronic VHB in Cotonou. Methods: This was a descriptive cross-sectional study with a retrospective collection of data from January 1st, 2015 to December 31st, 2016 (24 months) and prospective from May to August 2017 (4 months). Chronic VHB patients treated with TDF for at least 6 months were included. The non-detectability of HBV DNA and the normalization of aminotransferases defined the virological and biochemical responses, respectively. The evaluation of the treatment response on liver fibrosis was done by using APRI score. Renal impairment was assessed by a reduction in glomerular filtration rate according to MDRD (Modifications of the Diet in Renal Disease) formula below 90 mL/min/1.73 m2. Results: In all, 42 patients treated with TDF were included. The average age was 46.7 ± 13.8 years. The study population was predominantly male with a sex ratio of 2.5. Among the 42 patients treated with TDF for an average of 60 weeks (24 to 96 weeks), 36 patients (85.7%) had a virological response; 21 patients (50%) had a biochemical response. Virologic response was 70% at week 24 (W24), 92.6% at W48, 87.5% at W72 and 100% at W96 without significant difference between W24 and W48; between W48 and W72 then between W72 and W96. There was a regression of fibrosis and cirrhosis but not significantly. Renal involvement occurred in 3 out of 19 cases (15.8%) including a case of chronic end stage renal failure and 2 cases of mild chronic renal failure. Conclusion: The treatment with TDF is effective and globally safe in our patients with chronic viral hepatitis B in Cotonou.
References
[1]
ORGANISATION MONDIALE DE LA SANTE (OMS) (2015) Manuel pour l’élaboration et l’évaluation des plans nationaux de lutte contre l’hépatite virale: Document provisoire. Villars-sous-Yens (Suisse), OMS, 66 p.
[2]
Kodjoh, N. (2015) Situation de la lutte contre les hépatites B et C en Afrique. Medecine et Sante’ Tropicales, 25, 141-144.
[3]
Marcellin, P., Fabien, Z., Christophe, H., et al. (2016) Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France. Digestive Diseases and Sciences, 61, 3072-3083.
https://doi.org/10.1007/s10620-015-4027-8
[4]
Mingxing, H., Guoli, L., Hong, S., et al. (2017) TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China. BioMed Research International, 2017, Article ID: 2463197
https://doi.org/10.1155/2017/2463197
[5]
Fatemeh, B., Soheila, H., Maryam, K., et al. (2015) Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleoside-Analogue Naive Iranian Patients Treated for Chronic Hepatitis B. Hepatitis Monthly, 15, e25749.
[6]
Jae, H., Kim, S., Won, J., et al. (2015) Efficacy and Safety of Tenofovir in Nucleos(t)ide-Naïve Patients with Genotype C Chronic Hepatitis B in Real-Life Practice The Korean Journal of Internal Medicine, 30, 32-41.
https://www.ncbi.nlm.nih.gov/pubmed/25589833
[7]
Bulent, B., Ozlem, M.S., Asli, C., et al. (2013) Efficacy of Tenofovir in Patients with Lamivudine Failure Is Not Different from That in Nucleoside/Nucleotide Analogue-Naïve Patients with Chronic Hepatitis B. Antimicrobial Agents and Chemotherapy, 57, 1790-1796. https://doi.org/10.1128/AAC.02600-12
[8]
Camila, V.P., Cristiane, V.T., Thiago, K.G., et al. (2016) Efficacy of Entecavir and Tenofovir in Chronic Hepatitis B under Treatment in the Public Health System in Southern Brazil. Memórias do Instituto Oswaldo Cruz, 111, 252-257.
https://doi.org/10.1590/0074-02760150390
[9]
Calvin, Q.P., Huy T., Alan, Y., et al. (2014) Efficacy and Safety of Tenofovir Disoproxil Fumarate in Asian-Americans with Chronic Hepatitis B in Community Settings. PLOS ONE, 9, 1-7.
[10]
Dan-Hong, Y., Yuan-Jun, X., Nian-Feng, Z., et al. (2015) Tenofovir Disoproxil Fumarate Is Superior to Lamivudine plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients. World Journal of Gastroenterology, 21, 2746-2753.
https://doi.org/10.3748/wjg.v21.i9.2746
[11]
Sang, K.J., Kyung-Ah, K., So, Y.H., et al. (2015) Tenofovir Disoproxil Fumarate Monotherapy for Nucleos(t)ide Analogue-Naïve and Nucleos(t)ide Analogue-Experienced Chronic Hepatitis B Patients. Clinical and Molecular Hepatology, 21, 41-48. https://doi.org/10.3350/cmh.2015.21.1.41
[12]
Calvin, Q., Sing, C., Huy, T., et al. (2015) Similar Efficacy and Safety of Tenofovir in Asians and Non-Asians with Chronic Hepatitis B. World Journal of Gastroenterology, 21, 5124-5131.
[13]
Hyo, J.A., Myeong J.S., Jeong, W.J., et al. (2017) Treatment Efficacy and Safety of Tenofovir-Based Therapy in Chronic Hepatitis B: A Real Life Cohort Study in Korea. PLOS ONE, 12, e0170362. https://doi.org/10.1371/journal.pone.0170362
[14]
Sombié, R., Sangaré, L., Guingane, A., et al. (2015) Traitement de l’hépatite B chronique par les analogues de nucléos(t)ides. Journal Africain d’Hépato- Gastroentérologie, 9, 114-118.
[15]
Soon, K.L., Myeong, J.S., Seok H.K., et al. (2017) Safety and Efficacy of Tenofovir in Chronic Hepatitis B-Related Decompensated Cirrhosis. World Journal of Gastroenterology, 23, 2396-2403. https://doi.org/10.3748/wjg.v23.i13.2396
[16]
Sukran, K., Melda, T., Gulsun, C., et al. (2010) The Effectiveness of Nucleoside Analogues in Chronic Hepatitis B Patients Unresponsive to Interferon Therapy: Our Clinical Trials for One Year. Hepatitis Monthly, 10, 289-293.
[17]
Grace, C.L., Tin, N., David, M., et al. (2017) Efficacy and Safety of Tenofovir in Chronic Hepatitis B. Australian Real World Experience. World Journal of Hepatology, 9, 48-56.
[18]
Jordan, J., Chang, T., Jang, J.W., et al. (2013) The Impact of HVB Therapy on Fibrosis and Cirrhosis. Hepatology, 58, 98-107.
